Browsing Schizophrenia and Psychotic Disorders by Title
Now showing items 45-64 of 126
-
Estimating the Economic Value of Automated Virtual Reality Cognitive Therapy for Treating Agoraphobic Avoidance in Patients With Psychosis: Findings From the gameChange Randomized Controlled Clinical Trial
(2022-11)Background: An automated virtual reality cognitive therapy (gameChange) has demonstrated its effectiveness to treat agoraphobia in patients with psychosis, especially for high or severe anxious avoidance. Its economic ... -
Evidence base for early intervention in psychosis services in rural areas: A critical review
(2020-07)Aim: Early Intervention in Psychosis teams (EITs) are a growing entity internationally, yet they remain under-researched given challenges facing their delivery. Model adaptations include stand-alone services, a hub-and-spoke ... -
Examination of the neural basis of psychotic-like experiences in adolescence during processing of emotional faces
(2020-03)Contemporary theories propose that dysregulation of emotional perception is involved in the aetiology of psychosis. 298 healthy adolescents were assessed at age 14- and 19-years using fMRI while performing a facial emotion ... -
Excessive sleepiness in patients with psychosis: An initial investigation
(2021-01)Clinical experience indicates that excessive sleepiness and hypersomnia may be a common issue for patients with psychosis. Excessive sleepiness is typically ascribed to the sedating effects of antipsychotic medications but ... -
The Experience of Sleep Problems and Their Treatment in Young People at Ultra-High Risk of Psychosis: A Thematic Analysis
(2018-08)We view sleep disruption as a contributory causal factor in the development of psychotic experiences. Clinical trials indicate that psychological interventions targeting insomnia result in improvements in both sleep and ... -
A family perspective on parental psychosis: An interpretative phenomenological analysis study
(2022-11)Objectives: While one third of people with a psychotic disorder are a parent, there has been little research to date examining the consequences of this from a whole family perspective. This study investigates families ... -
Fear of illness recurrence and mental healthanxiety in people recovering from psychosis andcommon mental health problems
(2020-06)Objectives: It is well known that mental health problems can recur even after effective treatment, leading to an understandable fear of illness recurrence (FIR) and mental health anxiety (MHA). These may themselves contribute ... -
GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia
(2023-09)Involvement of the glutamate system, particularly N-methyl-D-aspartate (NMDA) receptor hypofunction, has long been postulated to be part of the pathophysiology of schizophrenia. An important development is provided by ... -
Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something
(2019-05-03)Since its first description in 1863, ‘hebephrenia’ has highlighted a group of patients characterised by an early onset of illness, formal thought disorder, bizarre behaviour and incongruent emotional expression. A proportion ... -
Hemizygous mutations in L1CAM in two unrelated male probands with childhood onset psychosis
(2020-06)Objective :To identify genes underlying childhood onset psychosis. Methods :Patients with onset of psychosis at age 13 or younger were identified from clinics across England, and they and their parents were exome sequenced ... -
Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk
(2023-03)Background: Preclinical and human data suggest that the onset of psychosis involves hippocampal glutamatergic dysfunction, driving hyperactivity/hyperperfusion in a hippocampal-midbrain-striatal circuit. Whether glutamatergic ... -
How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices
(2021-08)Background The magnitude of the superiority of antipsychotics over placebo is debated. One reason is that the effect-size index which is usually used in meta-analyses is in standard deviation units. Many other indices, ... -
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis
(2019-06)Introduction: In patients with schizophrenia, medication adherence is important for relapse prevention, and effective adherence monitoring is essential for treatment planning. A digital medicine system (DMS) has been ... -
Identifying effective characteristics of behavioral weight management interventions for people with serious mental illness: A systematic review with a qualitative comparative analysis
(2021-10)People with serious mental illness (SMI) have identified barriers to engaging in behavioral weight management interventions (BWMIs). We assessed whether BWMIs that addressed these barriers were more effective. First, we ... -
Identifying individuals at risk of developing psychosis: A systematic review of the literature in primary care services
(2023-01)Psychosis and related disorders are a major public health issue. Early identification and prevention for those at high risk (at-risk-mental-state, ARMS) is important. General practitioners (GPs) are often the first point ... -
‘If he feels better I'll feel better’ relationships with individuals at high-risk of developing psychosis
(2021-03)A large proportion of individuals with an at-risk mental state (ARMS) live at home and are supported by their families. Recommended treatment includes family intervention (FI), and therefore, understanding relationships ... -
The impact of Patient and Public Involvement in the SlowMo study: Reflections on peer innovation
(2021-09)Background: The SlowMo study demonstrated the effects of SlowMo, an eight-session digitally supported reasoning intervention, on paranoia in a large-scale randomized-controlled trial with 362 participants with schizophre ... -
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
(2019-07)Importance: Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether ... -
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
(2019-06)Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ...